Progression of renal damage in glycogen storage disease type I is associated to hyperlipidemia: a multicenter prospective Italian study

J Pediatr. 2015 Apr;166(4):1079-82. doi: 10.1016/j.jpeds.2014.12.015. Epub 2015 Jan 29.

Abstract

Angiotensin converting enzyme (ACE)-inhibitors decrease glomerular hyperfiltration but not microalbuminuria and proteinuria in glycogen storage disease type I. In the current study, we demonstrated that severe hyperlipidemia is associated with ACE-inhibitor ineffectiveness. We underline the importance of adequate metabolic control in glycogen storage disease type I. A combination therapy with ACE-inhibitors and lipid lowering drugs might be considered.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Child
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Forecasting*
  • Glomerular Filtration Rate / drug effects
  • Glycogen Storage Disease Type I / blood
  • Glycogen Storage Disease Type I / complications*
  • Glycogen Storage Disease Type I / drug therapy
  • Humans
  • Hyperlipidemias / blood
  • Hyperlipidemias / complications*
  • Hyperlipidemias / drug therapy
  • Hypolipidemic Agents / therapeutic use*
  • Incidence
  • Italy / epidemiology
  • Kidney Diseases / diagnosis
  • Kidney Diseases / epidemiology
  • Kidney Diseases / etiology*
  • Lipids / blood*
  • Male
  • Prospective Studies
  • Retrospective Studies
  • Young Adult

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Hypolipidemic Agents
  • Lipids